What is the current Tumor Liquid Biopsy Kit market size?

The Tumor Liquid Biopsy Kit market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033 with a future outlook of increased adoption.

What are the key drivers of the Tumor Liquid Biopsy Kit market?

Key drivers include increasing cancer prevalence and advancements in liquid biopsy technologies.

What challenges does the Tumor Liquid Biopsy Kit market face?

Challenges include high development costs and regulatory hurdles that impact market growth.

Which regions are leading the Tumor Liquid Biopsy Kit market?

North America and Europe are currently the regional leaders due to high healthcare expenditure.

Who are the top companies in the Tumor Liquid Biopsy Kit market?

Top companies include Illumina, Thermo Fisher, and Roche, which dominate the market with their innovative products.

What future opportunities can be expected in the market?

Future opportunities include increasing demand from emerging economies and growing applications in cancer diagnosis.

How will technology impact the Tumor Liquid Biopsy Kit market?

Advances in technologies like next-generation sequencing will significantly impact the market with improved diagnostic capabilities.

What is the current regulatory landscape for the Tumor Liquid Biopsy Kit market?

The regulatory landscape is complex with stringent FDA approvals required for new product launches.

How will the Tumor Liquid Biopsy Kit market evolve in the next 5 years?

The market will evolve with increased focus on non-invasive diagnostics and personalized medicine approaches.

Tumor Liquid Biopsy Kit Industry Size, Share & Growth Forecast 2033

Tumor Liquid Biopsy Kit by Application (Solid Tumor, Blood Cancer), by Types (Blood Samples, Urine Samples, NGS, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 154

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 154

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Tumor Liquid Biopsy Kit Market Size | CAGR 15.2 Forecast 2033

Tumor Liquid Biopsy Kit Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 154

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 154

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tumor Liquid Biopsy Kit Market Overview

The Tumor Liquid Biopsy Kit market refers to the industry that provides diagnostic kits for detecting and monitoring tumors through liquid biopsies. As the Tumor Liquid Biopsy Kit market size is expected to reach $1.4 billion by 2026, the growth outlook and market forecast indicate a promising future for the industry, driven by the increasing demand for non-invasive diagnostic techniques. The industry expansion is anticipated to be fueled by advancements in technology, rising cancer incidence, and growing awareness about the benefits of liquid biopsies. The scope of the market encompasses various types of kits, including PCR-based, NGS-based, and immunostaining-based kits, which are used in hospitals, research institutions, and pharmaceutical companies.

Loading chart…

The Tumor Liquid Biopsy Kit market is expected to grow at a CAGR of 18.5% during the forecast period from 2026 to 2033, driven by macro drivers such as increasing cancer incidence, rising demand for non-invasive diagnostic techniques, and advancements in technology. Key forces shaping the industry include technology shifts towards NGS-based kits, regulations supporting the use of liquid biopsies, and competitive intensity among market players. The largest region in the market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing awareness and adoption of liquid biopsies in the region.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biocept; Qiagen; Roche Diagnostics; Bio-Rad Laboratories; Myriad Genetics; Menarini-Silicon Biosystems; Cardiff Oncology; Guardant Health; Mdxhealth; Genomic Health (Exact Sciences); NeoGenomics; Thermo Fisher Scientific; Illumina; Amoy Diagnostics; Burning Rock Dx; Genetron; BGI; Novogene; Agena Bioscience (Mesa Labs, Inc.)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Tumor Liquid Biopsy Kit market is poised for significant growth, driven by increasing demand for non-invasive diagnostic techniques. The Tumor Liquid Biopsy Kit market size is expected to expand rapidly, with a substantial growth forecast over the next five years.

Growth Drivers2 items

Advances in next-generation sequencing technologies have improved the sensitivity and specificity of Tumor Liquid Biopsy Kits, driving adoption in clinical settings

Government initiatives and funding for cancer research have increased, leading to a rise in the development and use of Tumor Liquid Biopsy Kits for early cancer detection and monitoring

Restraints2 items

High development costs and complex regulatory frameworks are hindering the entry of new players into the Tumor Liquid Biopsy Kit market

Limited reimbursement options for liquid biopsy tests are restricting their adoption in some regions, affecting the overall Tumor Liquid Biopsy Kit market size

Opportunities2 items

The growing demand for personalized medicine is creating new opportunities for Tumor Liquid Biopsy Kit manufacturers to develop targeted therapies and companion diagnostics

Increasing collaborations between pharmaceutical companies and diagnostic manufacturers are driving innovation in the Tumor Liquid Biopsy Kit market, with a positive impact on the growth forecast

Challenges2 items

The Tumor Liquid Biopsy Kit market faces significant competition from established diagnostic technologies, such as tissue biopsies, which can limit market share gains

Ensuring the analytical validity and clinical utility of Tumor Liquid Biopsy Kits remains a major challenge, requiring ongoing investment in research and development

Market Segmentation

Loading chart…

The Tumor Liquid Biopsy Kit market can be segmented based on Application, which refers to the specific use cases of these kits in various cancer diagnostics and research settings. This segmentation category contributes significantly to the overall Tumor Liquid Biopsy Kit market size, as different applications have distinct requirements and demand patterns. Understanding the application-based segmentation is crucial for market players to tailor their products and strategies to meet the needs of specific customer groups, ultimately driving business growth in the Tumor Liquid Biopsy Kit segmentation.

The Types of Tumor Liquid Biopsy Kits, including subtypes such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), represent another vital segmentation category. Each subtype has its unique characteristics, advantages, and limitations, influencing the market size and dynamics. For instance, ctDNA-based kits are gaining popularity due to their non-invasive nature and high sensitivity, while CTCs are valued for their potential in providing comprehensive information about tumor biology. Analyzing the types and subtypes of Tumor Liquid Biopsy Kits helps stakeholders navigate the market taxonomy and identify opportunities for innovation and expansion.

Tumor Liquid Biopsy Kit Segmentation Breakdown8 items

Application

Solid Tumor

Blood Cancer

Types

Blood Samples

Urine Samples

NGS

Others

Regional Insights

Loading chart…

The Tumor Liquid Biopsy Kit market growth is expected to vary across regions, with North America being the largest region, driven by key factors such as high adoption of advanced diagnostic technologies, favorable policies and investments in healthcare infrastructure, and a mature ecosystem for research and development. The regional forecast indicates that North America will account for approximately 40% of the global market share.

The Asia Pacific region is expected to be the fastest-growing region, driven by increasing demographics with a high prevalence of cancer, growing infrastructure for healthcare and research, and rising investments in the biotechnology sector. Other key regions include Europe, driven by a strong ecosystem for research and development, and Latin America and Middle East & Africa, which are expected to experience significant growth due to improving infrastructure and increasing adoption of advanced diagnostic technologies.

Key Drivers by Region4 items

North America: high adoption of advanced diagnostic technologies, favorable policies and investments in healthcare infrastructure, mature ecosystem for research and development

Asia Pacific: increasing demographics with a high prevalence of cancer, growing infrastructure for healthcare and research, rising investments in the biotechnology sector

Europe: strong ecosystem for research and development, high adoption of advanced diagnostic technologies, favorable policies and investments in healthcare infrastructure

Latin America and Middle East & Africa: improving infrastructure, increasing adoption of advanced diagnostic technologies, growing investments in the biotechnology sector

Competitive Landscape

The Tumor Liquid Biopsy Kit market is moderately consolidated, with a mix of global players and local companies competing on various fronts, including pricing, distribution, product innovation, certifications, and regulatory approvals. The Tumor Liquid Biopsy Kit competitive landscape is driven by the need for companies to differentiate themselves through innovative products, strategic partnerships, and strong distribution networks. Key competitive levers include pricing strategies, product portfolio expansion, and investments in research and development to improve assay sensitivity and specificity.

Companies in this space are adopting various strategies to stay competitive, including mergers and acquisitions, partnerships, and product launches. Common challenges faced by these companies include margin pressure, compliance costs, and supply chain risks. To differentiate themselves, companies are focusing on technology advancements, service model innovations, and channel strength. Some companies are also exploring regional expansion, vertical integration, and premium pricing to maintain their competitive edge.

Biocept: regional expansion

Qiagen: innovation pipeline

Roche Diagnostics: premium pricing

Bio-Rad Laboratories: OEM tie-ups

Myriad Genetics: local manufacturing

Menarini-Silicon Biosystems: vertical integration

Key Tumor Liquid Biopsy Kit Companies19 items

Biocept

Qiagen

Roche Diagnostics

Bio-Rad Laboratories

Myriad Genetics

Menarini-Silicon Biosystems

Cardiff Oncology

Guardant Health

Mdxhealth

Genomic Health (Exact Sciences)

NeoGenomics

Thermo Fisher Scientific

Illumina

Amoy Diagnostics

Burning Rock Dx

Genetron

BGI

Novogene

Agena Bioscience (Mesa Labs, Inc.)

Market Ecosystem

The Tumor Liquid Biopsy Kit ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured as raw materials and components are transformed into kits, which are then distributed and used by end users. The ecosystem is shaped by the interactions and relationships among these participants, influencing the development, adoption, and use of Tumor Liquid Biopsy Kits.

Raw material/component suppliers — provide key kit components

OEMs / manufacturers — produce Tumor Liquid Biopsy Kits

Technology providers — develop underlying technologies

System integrators / EPCs — integrate kits into larger systems

Distributors / channel partners — distribute kits to end users

End users / buyers — use Tumor Liquid Biopsy Kits in research and diagnostics

Regulators/standards bodies — establish guidelines and standards

The flow of value in the Tumor Liquid Biopsy Kit ecosystem is influenced by control points, such as regulatory approvals and standards, which can impact the adoption of kits. Dependency risks, including input constraints and standards, can also affect the ecosystem. Switching costs and interoperability requirements may limit the ability of end users to change kits or suppliers. As part of a broader value chain analysis, understanding these dynamics is crucial to navigating the complex Tumor Liquid Biopsy Kit ecosystem, which may differ by region due to varying regulatory environments and market conditions.

Recent Industry Insights

The Tumor Liquid Biopsy Kit industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships, such as the collaboration between Guardant Health and Astellas Pharma, have driven innovation in the field. Additionally, mergers and acquisitions, including the acquisition of Thrive Earlier Detection by Exact Sciences, have led to the expansion of product portfolios and technological capabilities.

Furthermore, recent product launches, such as the introduction of Foundation Medicine's liquid biopsy test, have enhanced the diagnostic capabilities of Tumor Liquid Biopsy Kits. Regulatory changes, including the FDA's approval of Guardant360, have also played a crucial role in shaping the industry. The shift in consumer trends towards non-invasive diagnostic tests has fueled the growth of the Tumor Liquid Biopsy Kit market, with companies like Illumina securing funding rounds to support the development of new technologies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Tumor Liquid Biopsy Kit market outlook. The market attractiveness is high due to the increasing demand for non-invasive cancer diagnosis and monitoring. The competitive intensity is moderate, with key players investing heavily in research and development to improve the accuracy and sensitivity of their kits.

The long-term outlook for the Tumor Liquid Biopsy Kit market is positive, driven by advancements in genomics and precision medicine. The innovation landscape is rapidly evolving, with new technologies and products being launched regularly. However, the demand–supply balance is a key concern, with some regions facing shortages of skilled personnel to interpret test results. Key risk factors include regulatory challenges and reimbursement issues, which can impact market growth.

12 items

1. Executive Summary

2. Tumor Liquid Biopsy Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tumor Liquid Biopsy Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Tumor Liquid Biopsy Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Tumor Liquid Biopsy Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Tumor Liquid Biopsy Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Tumor Liquid Biopsy Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Tumor Liquid Biopsy Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Tumor Liquid Biopsy Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Tumor Liquid Biopsy Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Tumor Liquid Biopsy Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Tumor Liquid Biopsy Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tumor Liquid Biopsy Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Tumor Liquid Biopsy Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Tumor Liquid Biopsy Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Tumor Liquid Biopsy Kit Market Competition by Key Manufacturers

9.1. Global Tumor Liquid Biopsy Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Tumor Liquid Biopsy Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Biocept

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Qiagen

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Roche Diagnostics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bio-Rad Laboratories

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Myriad Genetics

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Menarini-Silicon Biosystems

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cardiff Oncology

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Guardant Health

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Mdxhealth

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Genomic Health (Exact Sciences)

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. NeoGenomics

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Thermo Fisher Scientific

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Illumina

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Amoy Diagnostics

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Burning Rock Dx

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Genetron

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. BGI

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Novogene

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Agena Bioscience (Mesa Labs, Inc.)

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tumor Liquid Biopsy Kit Market

Figure 4: Global Tumor Liquid Biopsy Kit Market: Drivers

Figure 5: Global Tumor Liquid Biopsy Kit Market: Challenges

Figure 6: Global Tumor Liquid Biopsy Kit Market: Trends

Figure 7: Global Tumor Liquid Biopsy Kit Market: Opportunity

Figure 8: Global Tumor Liquid Biopsy Kit Market: Restraint

Figure 9: Global Tumor Liquid Biopsy Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Tumor Liquid Biopsy Kit Market Value (USD Million) By Region

Figure 19: Global Tumor Liquid Biopsy Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Tumor Liquid Biopsy Kit Market Value (USD Million) By Region

Figure 27: Global Tumor Liquid Biopsy Kit Market Share (%) By: Regions (2032)

Figure 28: Global Tumor Liquid Biopsy Kit Market Volume (K) By Region

Figure 29: Global Tumor Liquid Biopsy Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Tumor Liquid Biopsy Kit Market Value (USD Million) By Region

Figure 37: Global Tumor Liquid Biopsy Kit Market Share (%) By: Regions (2032)

Figure 38: Global Tumor Liquid Biopsy Kit Market Volume (K) By Region

Figure 39: Global Tumor Liquid Biopsy Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

133 items

Table 1: Market Segmentation Analysis

Table 2: Global Tumor Liquid Biopsy Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Tumor Liquid Biopsy Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Tumor Liquid Biopsy Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Tumor Liquid Biopsy Kit Market Value (USD Million) By Region

Table 14: Global Tumor Liquid Biopsy Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Tumor Liquid Biopsy Kit Market Volume (K) By Region

Table 31: Global Tumor Liquid Biopsy Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Tumor Liquid Biopsy Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Tumor Liquid Biopsy Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Tumor Liquid Biopsy Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Biocept Basic Information And Sales Area

Table 52: Biocept. Products Portfolio

Table 53: Qiagen Basic Information And Sales Area

Table 54: Qiagen. Products Portfolio

Table 55: Roche Diagnostics Basic Information And Sales Area

Table 56: Roche Diagnostics. Products Portfolio

Table 57: Bio-Rad Laboratories Basic Information And Sales Area

Table 58: Bio-Rad Laboratories. Products Portfolio

Table 59: Myriad Genetics Basic Information And Sales Area

Table 60: Myriad Genetics. Products Portfolio

Table 61: Menarini-Silicon Biosystems Basic Information And Sales Area

Table 62: Menarini-Silicon Biosystems. Products Portfolio

Table 63: Cardiff Oncology Basic Information And Sales Area

Table 64: Cardiff Oncology. Products Portfolio

Table 65: Guardant Health Basic Information And Sales Area

Table 66: Guardant Health. Products Portfolio

Table 67: Mdxhealth Basic Information And Sales Area

Table 68: Mdxhealth. Products Portfolio

Table 69: Genomic Health (Exact Sciences) Basic Information And Sales Area

Table 70: Genomic Health (Exact Sciences). Products Portfolio

Table 71: NeoGenomics Basic Information And Sales Area

Table 72: NeoGenomics. Products Portfolio

Table 73: Thermo Fisher Scientific Basic Information And Sales Area

Table 74: Thermo Fisher Scientific. Products Portfolio

Table 75: Illumina Basic Information And Sales Area

Table 76: Illumina. Products Portfolio

Table 77: Amoy Diagnostics Basic Information And Sales Area

Table 78: Amoy Diagnostics. Products Portfolio

Table 79: Burning Rock Dx Basic Information And Sales Area

Table 80: Burning Rock Dx. Products Portfolio

Table 81: Genetron Basic Information And Sales Area

Table 82: Genetron. Products Portfolio

Table 83: BGI Basic Information And Sales Area

Table 84: BGI. Products Portfolio

Table 85: Novogene Basic Information And Sales Area

Table 86: Novogene. Products Portfolio

Table 87: Agena Bioscience (Mesa Labs, Inc.) Basic Information And Sales Area

Table 88: Agena Bioscience (Mesa Labs, Inc.). Products Portfolio

Table 89: Global Market Value (USD Million) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Value (USD Million) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Market Volume (K) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Volume (K) (2025-2032) By Types

Table 96: Global Market Share (%) By Types (2032)

Table 97: Global Tumor Liquid Biopsy Kit Market Value (USD Million) By Region

Table 98: Global Tumor Liquid Biopsy Kit Market Share (%) By Region (2025-2032)

Table 99: North America Market Value (USD Million) (2025-2032) By Country

Table 100: North America Market Value (USD Million) (2025-2032) By Application

Table 101: North America Market Value (USD Million) (2025-2032) By Types

Table 102: Europe Market Value (USD Million) (2025-2032) By Country

Table 103: Europe Market Value (USD Million) (2025-2032) By Application

Table 104: Europe Market Value (USD Million) (2025-2032) By Types

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 106: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 108: South America Market Value (USD Million) (2025-2032) By Country

Table 109: South America Market Value (USD Million) (2025-2032) By Application

Table 110: South America Market Value (USD Million) (2025-2032) By Types

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 112: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 114: Global Tumor Liquid Biopsy Kit Market Volume (K) By Region

Table 115: Global Tumor Liquid Biopsy Kit Market Share (%) By Region (2025-2032)

Table 116: North America Market Volume (K) (2025-2032) By Country

Table 117: North America Market Volume (K) (2025-2032) By Application

Table 118: North America Market Volume (K) (2025-2032) By Types

Table 119: Europe Market Volume (K) (2025-2032) By Country

Table 120: Europe Market Volume (K) (2025-2032) By Application

Table 121: Europe Market Volume (K) (2025-2032) By Types

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 123: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 125: South America Market Volume (K) (2025-2032) By Country

Table 126: South America Market Volume (K) (2025-2032) By Application

Table 127: South America Market Volume (K) (2025-2032) By Types

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 129: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 131: Research Programs/Design For This Report

Table 132: Key Data Information From Secondary Sources

Table 133: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Tumor Liquid Biopsy Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biocept; Qiagen; Roche Diagnostics; Bio-Rad Laboratories; Myriad Genetics; Menarini-Silicon Biosystems; Cardiff Oncology; Guardant Health; Mdxhealth; Genomic Health (Exact Sciences); NeoGenomics; Thermo Fisher Scientific; Illumina; Amoy Diagnostics; Burning Rock Dx; Genetron; BGI; Novogene; Agena Bioscience (Mesa Labs, Inc.)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options